PMID- 28514853
OWN - NLM
STAT- MEDLINE
DCOM- 20180409
LR  - 20180907
IS  - 1543-8392 (Electronic)
IS  - 1543-8384 (Linking)
VI  - 14
IP  - 7
DP  - 2017 Jul 3
TI  - Targeting the Central Nervous System (CNS): A Review of Rabies Virus-Targeting 
      Strategies.
PG  - 2177-2196
LID - 10.1021/acs.molpharmaceut.7b00158 [doi]
AB  - The transport of drugs across the blood-brain barrier is challenging. The use of 
      peptide sequences derived from viruses with a central nervous system (CNS) 
      tropism is one elegant option. A prominent example is the rabies virus 
      glycopeptide-29 (RVG-29), which is said to enable a targeted brain delivery. 
      Although the entry mechanism of the rabies virus into the CNS is very well 
      characterized, it is unknown whether RVG-29-functionalized drug delivery systems 
      (DDSs) follow this pathway. RVG-29-functionalized DDSs present themselves with 
      modifications of the RVG-29 peptide sequence and different physicochemical 
      properties compared to the rabies virus. To our surprise, the impact of these 
      changes on the functionality is completely neglected. This review explores 
      virus-related CNS-targeting strategies by comparing RVG-29-functionalized DDSs 
      with regard to their peptide modification, physiochemical properties and their 
      behavior in cell culture studies with a special focus on the original pathway of 
      rabies virus entry into the CNS.
FAU - Oswald, Mira
AU  - Oswald M
AUID- ORCID: 0000-0003-1494-5331
AD  - Chemical & Pharmaceutical Development, Merck KGaA , Frankfurter Strasse 250, 64293 
      Darmstadt, Germany.
FAU - Geissler, Simon
AU  - Geissler S
AD  - Chemical & Pharmaceutical Development, Merck KGaA , Frankfurter Strasse 250, 64293 
      Darmstadt, Germany.
FAU - Goepferich, Achim
AU  - Goepferich A
AD  - Department for Pharmaceutical Technology, University of Regensburg , 
      Universitatsstrasse 31, 94030 Regensburg, Germany.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20170616
PL  - United States
TA  - Mol Pharm
JT  - Molecular pharmaceutics
JID - 101197791
RN  - 0 (Glycoproteins)
SB  - IM
MH  - Animals
MH  - Blood-Brain Barrier/metabolism
MH  - Central Nervous System/*metabolism
MH  - Drug Delivery Systems/methods
MH  - Glycoproteins/*metabolism
MH  - Humans
MH  - Rabies virus/*metabolism
OTO - NOTNLM
OT  - CNS-targeting strategies
OT  - blood-brain barrier
OT  - rabies virus glycopeptide
EDAT- 2017/05/19 06:00
MHDA- 2018/04/10 06:00
CRDT- 2017/05/19 06:00
PHST- 2017/05/19 06:00 [pubmed]
PHST- 2018/04/10 06:00 [medline]
PHST- 2017/05/19 06:00 [entrez]
AID - 10.1021/acs.molpharmaceut.7b00158 [doi]
PST - ppublish
SO  - Mol Pharm. 2017 Jul 3;14(7):2177-2196. doi: 10.1021/acs.molpharmaceut.7b00158. 
      Epub 2017 Jun 16.